AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for N-acetylglutamate synthase, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8N159

UPID:

NAGS_HUMAN

Alternative names:

Amino-acid acetyltransferase

Alternative UPACC:

Q8N159; B2RAZ9; Q8IWR4

Background:

N-acetylglutamate synthase, mitochondrial, also known as Amino-acid acetyltransferase, plays a crucial role in ureagenesis by synthesizing N-acetylglutamate (NAG). NAG acts as an essential cofactor, modulating the activity of carbamoylphosphate synthase I (CPS1), a key enzyme in the urea cycle.

Therapeutic significance:

N-acetylglutamate synthase deficiency, a rare metabolic disorder, manifests as severe hyperammonemia, developmental delays, and neurological issues. This condition underscores the protein's critical role in metabolic pathways, highlighting the potential for targeted therapeutic strategies to manage or correct the enzyme's activity.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.